Results of the study


The results of the study will gradually be entered here.

SARS-CoV-2 Seroprevalence in Germany
A Population-Based Sequential Study in Seven Regions
Dtsch Arztebl Int 2021; 118: 824-31; DOI: 10.3238/arztebl.m2021.0364

1. Gornyk, D., Harries, M., Glöckner, S., Strengert, M., Kerrinnes, T., Heise, JK, … & Krause, G. (2021). SARS-CoV-2 seroprevalence in Germany: A population-based sequential study in seven regions. Deutsches Ärtzeblatt international, 118(48), 824.

2. Dulovic, A., Kessel, B., Harries, M., Becker, M., Ortmann, J., Griesbaum, J., … & Strengert, M. (2022). Comparative Magnitude and Persistence of Humoral SARS-CoV-2 Vaccination Responses in the Adult Population in Germany. Frontiers in immunology, 13.

3. Junker, D., Becker, M., Wagner, TR, Kaiser, PD, Maier, S., Grimm, TM, … & Schneiderhan-Marra, N. (2022). Antibody binding and ACE2 binding inhibition is significantly reduced for the Omicron variant compared to all other variants of concern. MedRxiv, 2021-12.

SARS-CoV-2 seroprevalence in Germany
A population-based sequential study in seven regions
SARS-CoV-2 seroprevalence in Germany—a population-based sequential study in seven regions
Dtsch Ärzteebl Int 2021; 118:824-31; DOI: 10.3238/arztebl.m2021.0364

Your browser can not display embedded frames: You can access the embedded page using the following link: Server dashboard

MuSPAD Logo blue